Nuvo, Covidien deal

Mallinckrodt will return to Nuvo U.S. rights to Pennsaid diclofenac and Pennsaid 2% and pay Nuvo $10 million to settle litigation between the companies. Mallinckrodt marketed Pennsaid, a topical NSAID gel formulation of diclofenac, to treat pain associated with osteoarthritis (OA) of the knee. Nuvo said it will seek a new U.S. partner. Mallinckrodt, which was spun out of Covidien last year, had U.S. rights to Pennsaid from Nuvo under a 2009 deal. ...